Nuvation Bio (NUVB) Cash from Operations (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Cash from Operations of 5069000.0 for Q1 2026, up 111.89% year-over-year from 2392261.8 in Q1 2025, and up 117.05% quarter-over-quarter from 29727000.0 in Q4 2025.
Nuvation Bio (NUVB) Cash from Operations (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Cash from Operations for 7 consecutive years, with 5069000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 111.89% year-over-year to 5069000.0; the TTM figure through Mar 2026 stood at 125731000.0 (up 20.09% YoY), while the FY2025 annual figure was 173427000.0, down 32.98% from the prior year.
- Cash from Operations grew to 5069000.0 in Q1 2026 per NUVB's latest filing, from 29727000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 5069000.0 in Q1 2026 and bottomed at 52895000.0 in Q3 2025.
- Historically, Cash from Operations has averaged 27228117.65 across 5 years, with a median of 26918000.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Operations sank 208.08% — and 2026, when it surged 111.89%.
- Nuvation Bio's Cash from Operations stood at 16169000.0 in 2022, then increased by 7.05% to 15029000.0 in 2023, then tumbled by 208.08% to 46302000.0 in 2024, then soared by 35.8% to 29727000.0 in 2025, then soared by 117.05% to 5069000.0 in 2026.
- Business Quant data shows NUVB's Cash from Operations at 5069000.0 in Q1 2026, 29727000.0 in Q4 2025, and 52895000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | -43.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.00 Mn |
| Jun 30, 2026 | -43.00 Mn |
| Mar 31, 2026 | 5.07 Mn |
| Mar 31, 2026 | 5.07 Mn |
| Dec 31, 2025 | -29.73 Mn |
| Dec 31, 2025 | -29.73 Mn |
| Sep 30, 2025 | -52.90 Mn |
| Sep 30, 2025 | -52.90 Mn |
| Jun 30, 2025 | -48.18 Mn |
| Jun 30, 2025 | -48.18 Mn |
| Mar 31, 2025 | -42.63 Mn |
| Mar 31, 2025 | -42.63 Mn |
| Dec 31, 2024 | -46.30 Mn |
| Dec 31, 2024 | -46.30 Mn |
| Sep 30, 2024 | -31.09 Mn |
| Sep 30, 2024 | -31.09 Mn |
| Jun 30, 2024 | -37.32 Mn |
| Jun 30, 2024 | -37.32 Mn |
| Mar 31, 2024 | -15.70 Mn |
| Mar 31, 2024 | -15.70 Mn |